Skip to main content

Research

The latest research in type 1 diabetes, type 2 diabetes, prediabetes, and beyond. Here you’ll find information on experimental therapies, new data and results, and scientific findings.

Closed loop systems, stem cells, smart insulin, and more!
Why the company decided against pursuing its type 2 GLP-1 drug Victoza to the FDA for use in type 1 diabetes.
Plus, an interview with Dr. Anne Peters on 23andMe and the future of individualized care.
Breaking news from Stockholm, Sweden, where our team is on the ground at the European Association for the Study of Diabetes (EASD) Conference – one of the largest...
A 38% decrease in cardiovascular death is exciting, but our work is nowhere near done.
Zosano Pharma is making early progress with an innovative patch-based glucagon delivery system for severe hypoglycemia, recently announcing that it has completed...
When might this product reach the market?
And “potentially transformative” advances coming for type 1 diabetes.
What are the projections for 2040?
Grant will fund up to five projects focused on genetic risk for type 1 diabetes.
A new study from Dr. Doug Melton’s team provides hope for the future of stem cell treatment in diabetes. But there’s still a long way to go.
Crowdfunding – say hello to diabetes with Diabetes Research Connection.
Incredible presentation from CEO Derek Rapp on the state of the foundation. Plus, updates on the Bionic Pancreas and ViaCyte!
15 year-old Amelia Cooper was one of over 150 children who visited Washington, DC as delegates for JDRF Children's Congress on July 13-15. She and other children and...
By Christie Auyeung Last summer, the Diabetes Research Connection (DRC) officially launched a novel crowdfunding platform that directly connects donors with early-career...
Moving the field closer to finding a cure in humans through an innovative tissue donation program – find out how you can support this work!
TZD drug pioglitazone becomes second-ever diabetes drug to reduce heart disease and first to reduce strokes. Who might this benefit most?
Strong results from the IMPACT study in low-A1c users.
Type 1 diabetes has been prevented and cured in more than 500 ways in mice, but never in humans. nPOD researchers are trying to change that, one donated organ at a time.
Highlights from the first study of a commercial automated insulin delivery device. Plus, Medtronic’s latest software updates!

Pages